Company news

Adial Pharmaceuticals, Inc (NASDAQ:ADIL) news

Adial Pharmaceuticals, Inc news releases on 6ix. Latest, Sep 30, 2026: Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals, Inc (NASDAQ:ADIL) news

Press releases & updates

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04